CTLA4 and neoplasm: Additionally, investigating agents that specifically modulate the activity of Th subsets and designing combination therapies—such as combining PD-1 inhibitors with agents that block Treg activity (e.g., anti-CD25 or anti-CTLA-4 antibodies)—are crucial for enhancing the overall anti-tumor immune response.